125 related articles for article (PubMed ID: 2674337)
1. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.
Swan F; Velasquez WS; Tucker S; Redman JR; Rodriguez MA; McLaughlin P; Hagemeister FB; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1518-27. PubMed ID: 2674337
[TBL] [Abstract][Full Text] [Related]
2. Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.
Milanovic N; Matkovic S; Ristic D; Jelic S; Petrovic M
J BUON; 2012; 17(3):497-501. PubMed ID: 23033288
[TBL] [Abstract][Full Text] [Related]
3. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.
Suki S; Swan F; Tucker S; Fritsche HA; Redman JR; Rodriguez MA; McLaughlin P; Romaguera J; Hagemeister FB; Velasquez WS
Leuk Lymphoma; 1995 Jun; 18(1-2):87-92. PubMed ID: 8580834
[TBL] [Abstract][Full Text] [Related]
4. Predictive model for prognosis in advanced diffuse histiocytic lymphoma.
Danieu L; Wong G; Koziner B; Clarkson B
Cancer Res; 1986 Oct; 46(10):5372-9. PubMed ID: 3530438
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
7. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma.
Avilés A; Zepeda G; Díaz-Maqueo JC; Rodriguez L; Guzmán R; García EL; Talavera A
Leuk Lymphoma; 1992 May; 7(1-2):135-8. PubMed ID: 1472924
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. Serum beta 2-microglobulin in malignant lymphoma.
Hagberg H; Killander A; Simonsson B
Cancer; 1983 Jun; 51(12):2220-5. PubMed ID: 6189572
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
Litam P; Swan F; Cabanillas F; Tucker SL; McLaughlin P; Hagemeister FB; Rodriguez MA; Velasquez WS
Ann Intern Med; 1991 May; 114(10):855-60. PubMed ID: 2014946
[TBL] [Abstract][Full Text] [Related]
11. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase.
Rodriguez J; Pugh WC; Romaguera JE; Luthra R; Hagemeister FB; McLaughlin P; Rodriguez MA; Swan F; Cabanillas F
Ann Oncol; 1994 Nov; 5(9):847-9. PubMed ID: 7848887
[TBL] [Abstract][Full Text] [Related]
12. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia.
Kantarjian HM; Smith T; Estey E; Polyzos A; O'Brien S; Pierce S; Beran M; Feldman E; Keating MJ
Am J Med; 1992 Dec; 93(6):599-604. PubMed ID: 1466355
[TBL] [Abstract][Full Text] [Related]
14. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
15. Serum beta 2-microglobulin in patients with adult T-cell leukemia.
Tsuda H; Ishii T; Sawada T; Takatsuki K
Acta Haematol; 1991; 86(1):31-5. PubMed ID: 1950359
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
17. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
Iakovleva SV; Andreeva NE; Izgorodin AS
Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
[TBL] [Abstract][Full Text] [Related]
18. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.
Jagannath S; Velasquez WS; Tucker SL; Fuller LM; McLaughlin PW; Manning JT; North LB; Cabanillas FC
J Clin Oncol; 1986 Jun; 4(6):859-65. PubMed ID: 2423653
[TBL] [Abstract][Full Text] [Related]
19. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
Ferreri AJ; Blay JY; Reni M; Pasini F; Spina M; Ambrosetti A; Calderoni A; Rossi A; Vavassori V; Conconi A; Devizzi L; Berger F; Ponzoni M; Borisch B; Tinguely M; Cerati M; Milani M; Orvieto E; Sanchez J; Chevreau C; Dell'Oro S; Zucca E; Cavalli F
J Clin Oncol; 2003 Jan; 21(2):266-72. PubMed ID: 12525518
[TBL] [Abstract][Full Text] [Related]
20. Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma.
Anderson H; Scarffe JH; Swindell R; Crowther D
Eur J Cancer Clin Oncol; 1983 Mar; 19(3):327-31. PubMed ID: 6190656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
